Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Ipilimumab in Metastatic melanoma: NCT07504796 Clinical Landscape Report 2026
18 September 2026
NCT07504796 clinical landscape for Metastatic melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Universal allogeneic anti-CD19/BCMA CAR T-cells(The Children's Hospital of Zhejiang University School of Medicine) in Granulomatosis With Polyangiitis: NCT07507201 Clinical Landscape Report 2026
18 September 2026
NCT07507201 clinical landscape for Granulomatosis With Polyangiitis: endpoints, sponsor, phase, geography, readouts, asset context and development white spac…
9 min read
Pelcitoclax in Acute Myeloid Leukemia: NCT07508982 Clinical Landscape Report 2026
18 September 2026
NCT07508982 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
U96-CAR-T-Cells(The First Affiliated Hospital of Soochow University) in B-Cell Leukemia: NCT07511426 Clinical Landscape Report 2026
18 September 2026
NCT07511426 clinical landscape for B-Cell Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Axatilimab-csfr in Acute Myeloid Leukemia: NCT07511062 Clinical Landscape Report 2026
18 September 2026
NCT07511062 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
YK012 in Systemic Lupus Erythematosus: NCT07512947 Clinical Landscape Report 2026
18 September 2026
NCT07512947 clinical landscape for Systemic Lupus Erythematosus: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Teclistamab in Refractory Multiple Myeloma: ISRCTN50499387 Clinical Landscape Report 2026
18 September 2026
ISRCTN50499387 clinical landscape for Refractory Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Metformin Hydrochloride in Psoriasis vulgaris: NCT07516821 Clinical Landscape Report 2026
18 September 2026
NCT07516821 clinical landscape for Psoriasis vulgaris: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
ISH-0613 in Systemic Lupus Erythematosus: NCT07516639 Clinical Landscape Report 2026
18 September 2026
NCT07516639 clinical landscape for Systemic Lupus Erythematosus: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
CHT-105 in Lupus Nephritis: NCT07517536 Clinical Landscape Report 2026
18 September 2026
NCT07517536 clinical landscape for Lupus Nephritis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
CAR 70-BCMA CAR-T Cells(The General Hospital of Western Theater Command) in Plasma Cell Neoplasms: NCT07519187 Clinical Landscape Report 2026
18 September 2026
NCT07519187 clinical landscape for Plasma Cell Neoplasms: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
[68Ga] Pentixafor in Multiple Myeloma: CTRI/2026/04/108288 Clinical Landscape Report 2026
18 September 2026
CTRI/2026/04/108288 clinical landscape for Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.